{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:23:22Z","timestamp":1781454202970,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41433-022-02315-9","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T18:06:08Z","timestamp":1669658768000},"page":"2197-2203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-0887","authenticated-orcid":false,"given":"Irmak","family":"Karaca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunay","family":"Uludag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Matsumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Regenold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Mobasserian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sohail","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1788-6306","authenticated-orcid":false,"given":"Moosa","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherin","family":"Lajevardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Dongchau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-4134","authenticated-orcid":false,"given":"Hashem","family":"Ghoraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-8441","authenticated-orcid":false,"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"2315_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature Working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509\u201316. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057.","journal-title":"Am J Ophthalmol"},{"key":"2315_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/09273940591003828","volume":"13","author":"AM Abu El-Asrar","year":"2005","unstructured":"Abu El-Asrar AM, Herbort CP, Tabbara KF. Retinal vasculitis. Ocul Immunol Inflamm. 2005;13:415\u201333. https:\/\/doi.org\/10.1080\/09273940591003828.","journal-title":"Ocul Immunol Inflamm"},{"key":"2315_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10792-009-9301-3","volume":"30","author":"AM El-Asrar","year":"2010","unstructured":"El-Asrar AM, Herbort CP, Tabbara KF. A clinical approach to the diagnosis of retinal vasculitis. Int Ophthalmol. 2010;30:149\u201373. https:\/\/doi.org\/10.1007\/s10792-009-9301-3.","journal-title":"Int Ophthalmol"},{"key":"2315_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.icu.0000144386.05116.c5","volume":"15","author":"AP Ciardella","year":"2004","unstructured":"Ciardella AP, Prall FR, Borodoker N, Cunningham ET Jr. Imaging techniques for posterior uveitis. Curr Opin Ophthalmol. 2004;15:519\u201330. https:\/\/doi.org\/10.1097\/01.icu.0000144386.05116.c5.","journal-title":"Curr Opin Ophthalmol"},{"key":"2315_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10792-008-9263-x","volume":"30","author":"I Tugal-Tutkun","year":"2010","unstructured":"Tugal-Tutkun I, Herbort CP, Khairallah M, Angiography Scoring for Uveitis Working G. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30:539\u201352. https:\/\/doi.org\/10.1007\/s10792-008-9263-x.","journal-title":"Int Ophthalmol"},{"key":"2315_CR6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903\u201312. https:\/\/doi.org\/10.1001\/archopht.123.7.903.","journal-title":"Arch Ophthalmol"},{"key":"2315_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00417-014-2637-z","volume":"252","author":"HM Kang","year":"2014","unstructured":"Kang HM, Lee SC. Long-term progression of retinal vasculitis in Behcet patients using a fluorescein angiography scoring system. Graefes Arch Clin Exp Ophthalmol. 2014;252:1001\u20138. https:\/\/doi.org\/10.1007\/s00417-014-2637-z.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2315_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10792-017-0487-5","volume":"38","author":"O Balci","year":"2018","unstructured":"Balci O, Jeannin B, Herbort CP Jr. Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2018;38:527\u201339. https:\/\/doi.org\/10.1007\/s10792-017-0487-5.","journal-title":"Int Ophthalmol"},{"key":"2315_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-020-00245-w","volume":"6","author":"MA Sadiq","year":"2020","unstructured":"Sadiq MA, Hassan M, Afridi R, Halim MS, Do DV, Sepah YJ, et al. Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study. Int J Retin Vitreous. 2020;6:47. https:\/\/doi.org\/10.1186\/s40942-020-00245-w","journal-title":"Int J Retin Vitreous"},{"key":"2315_CR10","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67:1656\u201362. https:\/\/doi.org\/10.1136\/ard.2007.080432.","journal-title":"Ann Rheum Dis"},{"key":"2315_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/BOR.0000000000000271","volume":"28","author":"JT Rosenbaum","year":"2016","unstructured":"Rosenbaum JT, Sibley CH, Lin P. Retinal vasculitis. Curr Opin Rheumatol. 2016;28:228\u201335. https:\/\/doi.org\/10.1097\/BOR.0000000000000271.","journal-title":"Curr Opin Rheumatol"},{"key":"2315_CR12","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Mesquida M, Ad\u00e1n A, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet\u2019s disease: a 1-year follow-up study of 124 patients. Rheumatol (Oxf). 2014;53:2223\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/keu266.","journal-title":"Rheumatol (Oxf)"},{"key":"2315_CR13","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1097\/IAE.0000000000000624","volume":"35","author":"PK Sharma","year":"2015","unstructured":"Sharma PK, Markov GT, Bajwa A, Foster CS. Long-Term Efficacy of Systemic Infliximab in Recalcitrant Retinal Vasculitis. Retina. 2015;35:2641\u20136. https:\/\/doi.org\/10.1097\/IAE.0000000000000624.","journal-title":"Retina"},{"key":"2315_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","volume":"26","author":"H Eser Ozturk","year":"2018","unstructured":"Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the Treatment of Behcet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocul Immunol Inflamm. 2018;26:1005\u201314. https:\/\/doi.org\/10.1080\/09273948.2017.1355471","journal-title":"Ocul Immunol Inflamm"},{"key":"2315_CR15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","volume":"57","author":"B Atienza-Mateo","year":"2018","unstructured":"Atienza-Mateo B, Calvo-Rio V, Beltran E, Martinez-Costa L, Valls-Pascual E, Hernandez-Garfella M, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet\u2019s disease: multicentre retrospective study. Rheumatol (Oxf). 2018;57:856\u201364. https:\/\/doi.org\/10.1093\/rheumatology\/kex480.","journal-title":"Rheumatol (Oxf)"},{"key":"2315_CR16","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s10067-018-4133-z","volume":"37","author":"C Fabiani","year":"2018","unstructured":"Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Lopalco G, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol. 2018;37:2805\u20139. https:\/\/doi.org\/10.1007\/s10067-018-4133-z.","journal-title":"Clin Rheumatol"},{"key":"2315_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/art.39940","volume":"69","author":"V Calvo-R\u00edo","year":"2017","unstructured":"Calvo-R\u00edo V, Santos-G\u00f3mez M, Calvo I, Gonz\u00e1lez-Fern\u00e1ndez MI, L\u00f3pez-Montesinos B, Mesquida M, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2017;69:668\u201375. https:\/\/doi.org\/10.1002\/art.39940.","journal-title":"Arthritis Rheumatol"},{"key":"2315_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/09273948.2011.606593","volume":"19","author":"A Muselier","year":"2011","unstructured":"Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19:382\u20133. https:\/\/doi.org\/10.3109\/09273948.2011.606593.","journal-title":"Ocul Immunol Inflamm"},{"key":"2315_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/09273948.2020.1712431","volume":"29","author":"RAW Wennink","year":"2021","unstructured":"Wennink RAW, Ayuso VK, de Vries LA, Vastert SJ, de Boer JH. Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis. Ocul Immunol Inflamm. 2021;29:21\u201325. https:\/\/doi.org\/10.1080\/09273948.2020.1712431.","journal-title":"Ocul Immunol Inflamm"},{"key":"2315_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/jop.2020.0081","volume":"37","author":"G Ucan Gunduz","year":"2021","unstructured":"Ucan Gunduz G, Yalcinbayir O, Cekic S, Yildiz M, Kilic SS. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. J Ocul Pharm Ther. 2021;37:236\u201340. https:\/\/doi.org\/10.1089\/jop.2020.0081.","journal-title":"J Ocul Pharm Ther"},{"key":"2315_CR21","first-page":"S34","volume":"34","author":"M Santos-G\u00f3mez","year":"2016","unstructured":"Santos-G\u00f3mez M, Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, Mesquida M, Ad\u00e1n A, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet\u2019s disease: results of a multicentre open-label study. Clin Exp Rheumatol 2016;34:S34\u2013S40.","journal-title":"Clin Exp Rheumatol"},{"key":"2315_CR22","doi-asserted-by":"publisher","first-page":"151 e1","DOI":"10.1016\/j.jaapos.2019.02.006","volume":"23","author":"N Ashkenazy","year":"2019","unstructured":"Ashkenazy N, Saboo US, Abraham A, Ronconi C, Cao JH. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis. J AAPOS. 2019;23:151 e1\u2013151 e5. https:\/\/doi.org\/10.1016\/j.jaapos.2019.02.006.","journal-title":"J AAPOS"},{"key":"2315_CR23","doi-asserted-by":"publisher","unstructured":"Maleki A, Garcia CM, Asgari S, Manhapra A, Foster CS Response to the Second TNF-alpha Inhibitor (Adalimumab or Infliximab) after Failing the First One in Refractory Idiopathic Inflammatory Retinal Vascular Leakage. Ocul Immunol Inflamm. 2021:1-10. https:\/\/doi.org\/10.1080\/09273948.2020.1869787.","DOI":"10.1080\/09273948.2020.1869787"},{"key":"2315_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","volume":"183","author":"YJ Sepah","year":"2017","unstructured":"Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. Am J Ophthalmol. 2017;183:71\u201380. https:\/\/doi.org\/10.1016\/j.ajo.2017.08.019.","journal-title":"Am J Ophthalmol"},{"key":"2315_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/09273948.2020.1817501","volume":"29","author":"A Maleki","year":"2021","unstructured":"Maleki A, Manhapra A, Asgari S, Chang PY, Foster CS, Anesi SD. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis. Ocul Immunol Inflamm. 2021;29:14\u201320. https:\/\/doi.org\/10.1080\/09273948.2020.1817501.","journal-title":"Ocul Immunol Inflamm"},{"key":"2315_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/09273948.2020.1763405","volume":"29","author":"R Farhat","year":"2021","unstructured":"Farhat R, Clavel G, Villeneuve D, Abdelmassih Y, Sahyoun M, Gabison E, et al. Sustained Remission with Tocilizumab in Refractory Relapsing Polychondritis with Ocular Involvement: A Case Series. Ocul Immunol Inflamm. 2021;29:9\u201313. https:\/\/doi.org\/10.1080\/09273948.2020.1763405.","journal-title":"Ocul Immunol Inflamm"},{"key":"2315_CR27","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","volume":"251","author":"A Ad\u00e1n","year":"2013","unstructured":"Ad\u00e1n A, Mesquida M, Lloren\u00e7 V, Espinosa G, Molins B, Hern\u00e1ndez MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627\u201332. https:\/\/doi.org\/10.1007\/s00417-013-2436-y.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2315_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","volume":"200","author":"N Vegas-Revenga","year":"2019","unstructured":"Vegas-Revenga N, Calvo-Rio V, Mesquida M, Adan A, Hernandez MV, Beltran E, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. Am J Ophthalmol. 2019;200:85\u201394. https:\/\/doi.org\/10.1016\/j.ajo.2018.12.019.","journal-title":"Am J Ophthalmol"},{"key":"2315_CR29","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1002\/sim.6198","volume":"33","author":"S Paul","year":"2014","unstructured":"Paul S, Zhang X. Small sample GEE estimation of regression parameters for longitudinal data. Stat Med. 2014;33:3869\u201381. https:\/\/doi.org\/10.1002\/sim.6198.","journal-title":"Stat Med"},{"key":"2315_CR30","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","volume":"121","author":"M Mesquida","year":"2014","unstructured":"Mesquida M, Molins B, Llorenc V, Sainz de la Maza M, Adan A. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121:2380\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2014.06.050.","journal-title":"Ophthalmology"},{"key":"2315_CR31","first-page":"31","volume":"33","author":"B Haraoui","year":"2006","unstructured":"Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 2006;33:31\u20136.","journal-title":"J Rheumatol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02315-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T19:03:45Z","timestamp":1690225425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02315-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02315-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"QDN serves on the Scientific Advisory Board for Affibody, Acelyrin, and Regeneron. The remaining authors declare that there are no conflicts of interest related to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}